Literature DB >> 25845294

Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome.

C Picard1, S Burtey2, C Bornet3, C Curti4, M Montana5, P Vanelle6.   

Abstract

Hemolytic uremic syndrome is a rare disease, frequently responsible for renal insufficiency in children. Recent findings have led to renewed interest in this pathology. The discovery of new gene mutations in the atypical form of HUS and the experimental data suggesting the involvement of the complement pathway in the typical form, open new perspectives for treatment. This review summarizes the current state of knowledge on both typical and atypical hemolytic uremic syndrome pathophysiology and examines new perspectives for treatment.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Analogue des récepteurs aux Shiga toxines; Eculizumab; Hemolytic uremic syndrome; Shiga toxin receptor analogues; Syndrome hémolytique urémique; Urtoxazumab

Mesh：

Substances：

Year:  2015        PMID： 25845294     DOI： 10.1016/j.patbio.2015.03.001

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN： 0369-8114


  12 in total

1.  Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma.

Authors:  Adarsh Das; Andrew Dean; Tim Clay
Journal:  BMJ Case Rep       Date:  2019-04-08

2.  Premise for Standardized Sepsis Models.

Authors:  Daniel G Remick; Alfred Ayala; Irshad H Chaudry; Craig M Coopersmith; Clifford Deutschman; Judith Hellman; Lyle Moldawer; Marcin F Osuchowski
Journal:  Shock       Date:  2019-01       Impact factor: 3.454

3.  Eculizumab Use in a Temporarily Dialysis-Dependent Patient With Shiga Toxin-Producing Escherichia Coli Hemolytic Uremic Syndrome With Neurological Complications.

Authors:  Bo Weber; Dominic Chan; Sandy Hammer
Journal:  J Pediatr Pharmacol Ther       Date:  2021-12-22

Review 4.  Direct cardiac involvement in childhood hemolytic-uremic syndrome: case report and review of the literature.

Authors:  Davide Rigamonti; Giacomo D Simonetti
Journal:  Eur J Pediatr       Date:  2016-09-23       Impact factor: 3.183

5.  Interventions for atypical haemolytic uraemic syndrome.

Authors:  Dan Pugh; Eoin D O'Sullivan; Fiona Ai Duthie; Philip Masson; David Kavanagh
Journal:  Cochrane Database Syst Rev       Date:  2021-03-23

6.  Whole-genome characterization of hemolytic uremic syndrome-causing Shiga toxin-producing Escherichia coli in Sweden.

Authors:  Ying Hua; Milan Chromek; Anne Frykman; Cecilia Jernberg; Valya Georgieva; Sverker Hansson; Ji Zhang; Ann Katrine Marits; Chengsong Wan; Andreas Matussek; Xiangning Bai
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

7.  Therapeutic Strategies to Protect the Central Nervous System against Shiga Toxin from Enterohemorrhagic Escherichia coli.

Authors:  Jorge Goldstein; Krista Nuñez-Goluboay; Alipio Pinto
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

8.  Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008.

Authors:  Gaute Reier Jenssen; Line Vold; Eirik Hovland; Hans-Jacob Bangstad; Karin Nygård; Anna Bjerre
Journal:  BMC Infect Dis       Date:  2016-06-13       Impact factor: 3.090

9.  A Case of Escherichia coli Hemolytic Uremic Syndrome in a 10-Year-Old Male With Severe Neurologic Involvement Successfully Treated With Eculizumab.

Authors:  Malia Rasa; James Musgrave; Keith Abe; Len Tanaka; Konstantine Xoinis; Bruce Shiramizu; Gretchen Foskett; Rhiana Lau
Journal:  J Investig Med High Impact Case Rep       Date:  2017-11-06

10.  Atypical hemolytic uremic syndrome triggered by varicella infection.

Authors:  Pauline Condom; Jean-Michel Mansuy; Stéphane Decramer; Jacques Izopet; Catherine Mengelle
Journal:  IDCases       Date:  2017-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.